Trump Pressures Eli Lilly and Pfizer with Tariff Threats for Overseas Production

Multinational pharmaceutical companies face pressure to relocate production to the U.S. / Reuters President Donald Trump has recently intensified his pressure on multinational pharmaceutical executives, warning them that they will face hefty tariffs if they do not relocate their production facilities to the United States. During a meeting at the White House, Trump discussed this issue directly with the CEOs of major pharmaceutical companies, including Eli Lilly and Pfizer. He indicated that medications produced outside the U.S. would incur tariffs of at least 25%, which he emphasized would take effect sooner than the previously stated deadline of April. The meeting highlighted Trump's insistence that companies must expedite the transfer of their production bases to the U.S. to avoid these tariffs. This announcement has heightened concern among South Korean pharmaceutical and biotech companies, which are now wary of potential tariff impacts if they continue to export drugs manufact...